Bulk Manufacturer of Controlled Substances Application: Noramco, Inc., 8381 [2021-02454]

Download as PDF 8381 Federal Register / Vol. 86, No. 23 / Friday, February 5, 2021 / Notices statement of the reasons why the Commission should grant such treatment. See 19 CFR 201.6. Documents for which confidential treatment by the Commission is properly sought will be treated accordingly. All information, including confidential business information and documents for which confidential treatment is properly sought, submitted to the Commission for purposes of this Investigation may be disclosed to and used: (i) By the Commission, its employees and Offices, and contract personnel (a) for developing or maintaining the records of this or a related proceeding, or (b) in internal investigations, audits, reviews, and evaluations relating to the programs, personnel, and operations of the Commission including under 5 U.S.C. Appendix 3; or (ii) by U.S. government employees and contract personnel,2 solely for cybersecurity purposes. All nonconfidential written submissions will be available for public inspection at the Office of the Secretary and on EDIS.3 This action is taken under the authority of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and of §§ 201.10 and 210.8(c) of the Commission’s Rules of Practice and Procedure (19 CFR 201.10, 210.8(c)). comments on or objections to the issuance of the proposed registration on or before April 6, 2021. Such persons may also file a written request for a hearing on the application on or before April 6, 2021. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on January 5, 2021, Sterling Pharma USA, LLC., 1001 Sheldon Drive, Suite 101, Cary, North Carolina 27513–2078, applied to be registered as an bulk manufacturer of the following basic class(es) of controlled substance(s): By order of the Commission. Issued: February 1, 2021. Lisa Barton, Secretary to the Commission. William T. McDermott, Assistant Administrator. Controlled substance Drug code Schedule Tetrahydrocannabinols ............... 7370 I The company plans to manufacture in bulk drug code 7370 (Tetrahydrocannabinols) exclusively from hemp extract, for distribution and sale to its customers. No other activity for this drug code is authorized for this registration. [FR Doc. 2021–02455 Filed 2–4–21; 8:45 am] BILLING CODE P [FR Doc. 2021–02435 Filed 2–4–21; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE Drug Enforcement Administration DEPARTMENT OF JUSTICE Bulk Manufacturer of Controlled Substances Application: Noramco, Inc. [Docket No. DEA–772] Bulk Manufacturer of Controlled Substances Application: Sterling Pharma USA, LLC AGENCY: Drug Enforcement Administration, Justice. ACTION: Notice of application. SUMMARY: Drug Enforcement Administration, Justice. ACTION: Notice of application. AGENCY: Sterling Pharma USA LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written jbell on DSKJLSW7X2PROD with NOTICES VerDate Sep<11>2014 18:53 Feb 04, 2021 Jkt 253001 Controlled substance Gamma Hydroxybutyric Acid .... Marihuana Extract ..................... Marihuana ................................. Tetrahydrocannabinols ............. Codeine-N-oxide ....................... Dihydromorphine ....................... Hydromorphinol ......................... Nabilone .................................... Codeine ..................................... Dihydrocodeine ......................... Oxycodone ................................ Hydromorphone ........................ Hydrocodone ............................. Levorphanol .............................. Morphine ................................... Drug code Schedule 2010 7350 7360 7370 9053 9145 9301 7379 9050 9120 9143 9150 9193 9220 9300 I I I I I I I II II II II II II II II The company plans to manufacture bulk active pharmaceutical ingredients (API) and reference standards for distribution to their customers. In reference to drug codes 7350 (Marihuana Extract), 7360 (Marihuana), and 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture these drugs as synthetics. No other activities for these drugs are authorized for this registration. William T. McDermott, Assistant Administrator. BILLING CODE P Drug Enforcement Administration 2 All contract personnel will sign appropriate nondisclosure agreements. 3 Electronic Document Information System (EDIS): https://edis.usitc.gov. In accordance with 21 CFR 1301.33(a), this is notice that on November 3, 2020, Noramco Inc, 1550 Olympic Drive, Athens Georgia 30601, applied to be registered as an bulk manufacturer of the following basic class(es) of controlled substance(s): SUPPLEMENTARY INFORMATION: [FR Doc. 2021–02454 Filed 2–4–21; 8:45 am] [Docket No. DEA–771] SUMMARY: Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. [OMB Number 1125–NEW] Noramco Inc has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before April 6, 2021. Such persons may also file a written request for a hearing on the application on or before April 6, 2021. ADDRESSES: Written comments should be sent to: Drug Enforcement PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 DEPARTMENT OF JUSTICE Agency Information Collection Activities; Proposed Collection; Comments Requested; FOIAXpress/ FOIA Public Access Link Executive Office for Immigration Review, Department of Justice. ACTION: 30-day notice. AGENCY: The Department of Justice (DOJ), Executive Office for Immigration Review (EOIR), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. SUMMARY: E:\FR\FM\05FEN1.SGM 05FEN1

Agencies

[Federal Register Volume 86, Number 23 (Friday, February 5, 2021)]
[Notices]
[Page 8381]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-02454]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-771]


Bulk Manufacturer of Controlled Substances Application: Noramco, 
Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Noramco Inc has applied to be registered as a bulk 
manufacturer of basic class(es) of controlled substance(s). Refer to 
Supplemental Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may file written comments on or objections to 
the issuance of the proposed registration on or before April 6, 2021. 
Such persons may also file a written request for a hearing on the 
application on or before April 6, 2021.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this 
is notice that on November 3, 2020, Noramco Inc, 1550 Olympic Drive, 
Athens Georgia 30601, applied to be registered as an bulk manufacturer 
of the following basic class(es) of controlled substance(s):

------------------------------------------------------------------------
                                           Drug
          Controlled substance             code          Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid...............    2010  I
Marihuana Extract.......................    7350  I
Marihuana...............................    7360  I
Tetrahydrocannabinols...................    7370  I
Codeine-N-oxide.........................    9053  I
Dihydromorphine.........................    9145  I
Hydromorphinol..........................    9301  I
Nabilone................................    7379  II
Codeine.................................    9050  II
Dihydrocodeine..........................    9120  II
Oxycodone...............................    9143  II
Hydromorphone...........................    9150  II
Hydrocodone.............................    9193  II
Levorphanol.............................    9220  II
Morphine................................    9300  II
------------------------------------------------------------------------

    The company plans to manufacture bulk active pharmaceutical 
ingredients (API) and reference standards for distribution to their 
customers.
    In reference to drug codes 7350 (Marihuana Extract), 7360 
(Marihuana), and 7370 (Tetrahydrocannabinols), the company plans to 
bulk manufacture these drugs as synthetics. No other activities for 
these drugs are authorized for this registration.

William T. McDermott,
Assistant Administrator.
[FR Doc. 2021-02454 Filed 2-4-21; 8:45 am]
BILLING CODE P